2023
Comprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test results
2021
Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient
Jacobs JW, Gisriel SD, Iyer K, Rinder HM. Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient. Journal Of Thrombosis And Thrombolysis 2021, 53: 945-949. PMID: 34697688, PMCID: PMC8544916, DOI: 10.1007/s11239-021-02591-4.Peer-Reviewed Original ResearchConceptsPartial thromboplastin timeLupus anticoagulantFVIII inhibitorsAsymptomatic patientsFactor VIIIComprehensive hematologic evaluationLife-threatening hemorrhageTypical laboratory findingsDistinctive clinical presentationFactor VIII inhibitorsRisk of thrombosisSigns of hemorrhageSevere bleeding diathesisCoagulation factor VIIIImmunosuppressive therapyClinical presentationClinical symptomsPathologic antibodiesVIII inhibitorsLaboratory findingsHematologic evaluationUnique presentationBleeding diathesisThromboplastin timeAutoantibodies
2001
The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress
Griffin M, Rinder H, Smith B, Tracey J, Kriz N, Li C, Rinder C. The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress. Anesthesia & Analgesia 2001, 93: 20-27. PMID: 11429331, DOI: 10.1097/00000539-200107000-00005.Peer-Reviewed Original ResearchConceptsCollagen-induced thrombus formationPlatelet hemostasis timePartial thromboplastin timeAntiplatelet effectProthrombin timeAntithrombin effectPlatelet activationProtamine reversalPlatelet functionDirect antiplatelet effectCollagen-dependent platelet activationDirect thrombin inhibitorL-arginyl-chloromethyl ketoneClot Signature AnalyzerEffect of heparinCollagen-induced platelet activationEffect of protamineArterial shear stressBlood lossCardiopulmonary bypassPlatelet dysfunctionProtamine ratioPlatelet aggregometryAnticoagulant effectThromboplastin time
1997
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers
Grossman D, Heald P, Wang C, Rinder H. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal Of The American Academy Of Dermatology 1997, 37: 409-413. DOI: 10.1016/s0190-9622(18)30738-2.Peer-Reviewed Original ResearchVenous leg ulcersFactor V Leiden mutationV Leiden mutationFactor V LeidenAnticardiolipin antibodiesLeg ulcersLeiden mutationV LeidenVenous leg ulcerationCommon risk factorsPartial thromboplastin timeAPC resistanceEnzyme-linked immunosorbentProtein C resistanceConsecutive patientsLeg ulcerationVenous thrombosisRisk factorsSkin ulcerationThromboplastin timeGeneral populationPatientsUlcersMethods TwentyLow APC ratioActivated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers
Grossman D, Heald P, Wang C, Rinder H. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal Of The American Academy Of Dermatology 1997, 37: 409-413. PMID: 9308555, DOI: 10.1016/s0190-9622(97)70141-5.Peer-Reviewed Original ResearchConceptsVenous leg ulcersFactor V Leiden mutationV Leiden mutationFactor V LeidenAnticardiolipin antibodiesLeg ulcersLeiden mutationV LeidenVenous leg ulcerationCommon risk factorsPartial thromboplastin timeAPC resistanceEnzyme-linked immunosorbentProtein C resistanceConsecutive patientsHypercoagulable stateLeg ulcerationVenous thrombosisRisk factorsSkin ulcerationThromboplastin timeGeneral populationPatientsUlcersLow APC ratio